GLP-1 Evidence

Article

Do GLP-1 drugs protect the kidneys? What the trials measured

Updated 4 min read 23 citations

Analytical chemistry bench fitted with glassware for titration and pH measurement
Jean-Pierre from Cosne-Cours-sur-Loire (Nièvre, Burgundy… · CC BY-SA 2.0 · Wikimedia Commons

Search "ozempic kidney disease" or "semaglutide chronic kidney disease" and you will find a lot of confident claims and very few links to an actual trial. The short version: the kidney signal is one of the better-supported non-weight findings for this drug class, but "protects the kidneys" means something narrower and more specific than most coverage implies — a slowed rate of decline in kidney function and fewer kidney-failure events in trials, not a treatment for kidney disease in general.

What "kidney outcomes" means in these trials

Trials in this area do not ask whether a drug "helps the kidneys." They track a defined composite: a sustained drop in estimated glomerular filtration rate (eGFR), progression to kidney failure, need for dialysis or transplant, or death from kidney or cardiovascular causes. A 2025 systematic review and meta-analysis of randomised trials in patients who already had chronic kidney disease examined GLP-1 receptor agonists against this kind of composite and reported consistent benefit [4]. A second, independent 2025 meta-analysis of randomised controlled trials reached the same conclusion looking at kidney and cardiovascular outcomes together [2].

This is not a brand-new finding dressed up for 2025. Earlier pooled analyses of cardiovascular outcome trials had already flagged a kidney signal riding alongside the cardiovascular one, going back to a 2019 systematic review and meta-analysis of cardiovascular outcome trials in type 2 diabetes [11] and confirmed again in a 2021 update using the same approach [23]. The kidney finding has been reproduced across several independent pooling exercises rather than resting on one headline trial — which is a meaningfully different evidence base than a single positive study.

Tirzepatide's own kidney data

The dual GIP/GLP-1 agonist has its own dedicated evidence. A post-hoc analysis of the SURPASS-4 trial compared tirzepatide against insulin glargine on kidney outcomes in people with type 2 diabetes and found benefit for tirzepatide on the composite renal endpoint [16]. That is a comparison against an active treatment known to be glucose-lowering, not a placebo, which strengthens the case that the effect is not simply "any glucose control helps the kidneys a bit."

Why weight-mediated versus direct matters here

The obesity-kidney relationship is itself well established in the literature: excess weight is an independent driver of kidney disease progression through several mechanisms, including glomerular hyperfiltration [21]. That creates the same interpretive problem this site raises on the cardiovascular outcomes page: a drug that produces large, sustained weight loss would be expected to help the kidneys somewhat regardless of any direct GLP-1 receptor effect on renal tissue. The trials as designed cannot cleanly separate "the kidneys got better because the person weighs less and has better blood pressure and glucose control" from "GLP-1 receptor activation has a direct protective mechanism in the kidney." Both are plausible; the trial data is agnostic between them, and it does not need to resolve that question for the finding to be clinically useful.

Reading the evidence at a glance

QuestionWhat the data showsConfidence
Does the drug class slow kidney function decline in people who already have CKD?Yes, across at least two independent 2025 meta-analyses of RCTsReasonably strong
Is the effect specific to one drug, or class-wide?Evidence spans multiple GLP-1 and dual-agonist molecules, including a head-to-head-style comparison for tirzepatideModerate — most depth is in diabetes populations
Is it a direct kidney effect or a downstream effect of weight and glucose control?Unresolved; both mechanisms are biologically plausibleOpen question
Does this mean the drug treats kidney disease on its own?No — it is adjunct evidence within diabetes and obesity care, not a kidney-disease indication in the sense a nephrology-specific drug would beDo not overstate

What this does not tell you

None of these trials enrolled people specifically because they had kidney disease and no diabetes or obesity — the populations are diabetes cohorts and, in the newer reviews, mixed CKD cohorts already on other kidney-protective therapy. That matters for anyone reading the headline "GLP-1 drugs cut kidney failure risk" and wondering if it applies to them specifically. It also does not tell you anything about dosing adjustments needed in advanced kidney impairment, which is a pharmacokinetic question the cited trials were not built to answer.

Common questions

Does this mean semaglutide or tirzepatide can replace an ACE inhibitor or SGLT2 inhibitor for kidney protection?
No trial has tested that substitution. The kidney benefit shows up in populations who were, in the main, already receiving standard-of-care kidney and cardiovascular medication. This is evidence for an additive benefit, not a replacement.
Is the kidney benefit bigger in people with more advanced kidney disease?
The 2025 CKD-specific review found benefit within a population that already had chronic kidney disease, which is a more direct answer than the earlier diabetes-cohort analyses could give, but subgroup effects by CKD stage are not something a short summary can respond to reliably — that detail sits inside the full review.
Does weight loss alone, without a GLP-1 drug, do the same thing for the kidneys?
Plausibly a comparable amount for the weight-mediated portion of the effect, but there is no head-to-head trial comparing equivalent weight loss achieved by diet against these drugs on kidney-specific endpoints.
Should someone with kidney disease ask about these drugs?
That is a conversation for a nephrologist or the physician managing kidney and diabetes care together, not a decision to make from a summary article. This article is for informational purposes and is not medical advice; talk to a clinician about your own situation.
Labelled chemical bottles standing together on a laboratory bench
564dude · CC BY-SA 3.0 · Wikimedia Commons
The evidence behind this page A stacked bar showing the composition of the 23 publications cited on this page by study type. 1282meta-analysis (12)randomised trial (8)review (1)other (2)
23 publications, 2018–2025. That is a mix with both trials and syntheses in it, which is the position from which a claim about cause is reasonable. Source: this page’s own citation list, below.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes Natale P, Green SC, Tunnicliffe DJ, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOIPubMed 39963952Full text
  2. Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials Badve SV, Bilal A, Lee MMY, et al. · The lancet. Diabetes & endocrinology · 2025 · Meta-analysis DOIPubMed 39608381
  3. Semaglutide effects on safety and cardiovascular outcomes in patients with overweight or obesity: a systematic review and meta-analysis Cleto AS, Schirlo JM, Beltrame M, et al. · International journal of obesity (2005) · 2025 · Meta-analysis DOIPubMed 39396098
  4. Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials Chen JY, Hsu TW, Liu JH, et al. · American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025 · Meta-analysis DOIPubMed 39863261
  5. Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis Shokravi A, Seth J, Mancini GBJ · Cardiovascular diabetology · 2025 · Meta-analysis DOIPubMed 41029853Full text
  6. Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials Apperloo EM, Neuen BL, Fletcher RA, et al. · The lancet. Diabetes & endocrinology · 2024 · Meta-analysis DOIPubMed 38991584
  7. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials Shi Q, Nong K, Vandvik PO, et al. · BMJ (Clinical research ed.) · 2023 · Meta-analysis DOIPubMed 37024129Full text
  8. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis Sattar N, McGuire DK, Pavo I, et al. · Nature medicine · 2022 · Meta-analysis DOIPubMed 35210595Full text
  9. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease Zhang Y, Jiang L, Wang J, et al. · Cardiovascular diabetology · 2022 · Meta-analysis DOIPubMed 36335326Full text
  10. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis Yamada T, Wakabayashi M, Bhalla A, et al. · Cardiovascular diabetology · 2021 · Meta-analysis DOIPubMed 33413348Full text
  11. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Kristensen SL, Rørth R, Jhund PS, et al. · The lancet. Diabetes & endocrinology · 2019 · Meta-analysis DOIPubMed 31422062
  12. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis Bethel MA, Patel RA, Merrill P, et al. · The lancet. Diabetes & endocrinology · 2018 · Meta-analysis DOIPubMed 29221659
  13. Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study Harrison SA, Frias JP, Lucas KJ, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · Randomised controlled trial DOIPubMed 38447814
  14. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial Deanfield J, Verma S, Scirica BM, et al. · Lancet (London, England) · 2024 · Randomised controlled trial DOIPubMed 39181597
  15. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Gastaldelli A, Cusi K, Fernández Landó L, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 35468325
  16. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial Heerspink HJL, Sattar N, Pavo I, et al. · The lancet. Diabetes & endocrinology · 2022 · Randomised controlled trial DOIPubMed 36152639
  17. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial Klausen MK, Jensen ME, Møller M, et al. · JCI insight · 2022 · Randomised controlled trial DOIPubMed 36066977Full text
  18. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Gerstein HC, Sattar N, Rosenstock J, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34215025
  19. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet (London, England) · 2019 · Randomised controlled trial DOIPubMed 31189511
  20. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics Nicholls SJ, Bhatt DL, Buse JB, et al. · American heart journal · 2024 · Clinical trial DOIPubMed 37758044
  21. Chronic Kidney Disease and Obesity Hojs R, Ekart R, Bevc S, et al. · Nephron · 2023 · Review DOIPubMed 37271131
  22. New Drug: Tirzepatide (Mounjaro(™)) Gettman L · The Senior care pharmacist · 2023 · Journal article DOIPubMed 36751934
  23. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Sattar N, Lee MMY, Kristensen SL, et al. · The lancet. Diabetes & endocrinology · 2021 · Journal article DOIPubMed 34425083